NASDAQ:GMAB 30 December 2025

AbbVie stock price: ABBV heads into Tuesday with epcoritamab trial in the crosshairs

AbbVie Inc shares ended Friday at $214.35, slipping $2.44, or roughly 1.1%. This drop came after AbbVie and partner Genmab announced their blood cancer drug epcoritamab did not demonstrate a clear overall-survival benefit in a late-stage trial.

19 January 2026

NASDAQ:GMAB·NYSE:ABBV·Pharmaceuticals·Stock Market

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie’s stock dropped on Friday after partner Genmab announced that a late-stage trial of epcoritamab failed to meet its primary endpoint of improving overall survival in blood cancer patients. AbbVie closed at $214.35, down 1.1%. Genmab’s U.S.-listed shares tumbled over 7%. The companies said they still expect data from two other late-stage epcoritamab trials in 2026, including studies combining the drug with standard chemotherapy and Bristol Myers Squibb’s Revlimid.

18 January 2026

NASDAQ:GMAB·NYSE:ABBV·NYSE:BMY·Pharmaceuticals·Stock Market

AbbVie stock heads into long weekend lower after mixed Epkinly trial readout; earnings next

AbbVie shares slipped 1.1% to close at $214.35 on Friday following mixed late-stage results for its lymphoma treatment, epcoritamab. In after-hours trading, the stock was last seen near $214.66, as U.S. indexes showed little movement.

17 January 2026

Earnings·NASDAQ:GMAB·NYSE:ABBV·Pharmaceuticals

Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus

Genmab A/S shares slid on Wednesday, down about 3.3% at $30.44 in New York trading, as investors weighed a late-stage pipeline cut and the closing steps of a major acquisition. The Nasdaq-listed ADR touched $30.36 after opening at $31.42.

31 December 2025

NASDAQ:GMAB·NASDAQ:MRUS·Pharmaceuticals·Stock Market

GMAB stock slides as Genmab scraps late-stage acasunlimab cancer therapy

Genmab A/S’s U.S.-listed shares fell 3.3% to $31.45 in Tuesday’s regular session. The stock traded between $31.40 and $32.06 after opening at $31.98, with about 1.9 million shares changing hands.

30 December 2025

NASDAQ:GMAB·Pharmaceutical Industry·Stock Market

Merus stock halted today as Genmab buyout closes: what happens to MRUS shares and the $97 cash payout

Merus N.V. shares were halted on Tuesday after Nasdaq said the final merger step in Denmark’s Genmab’s $97-a-share cash acquisition closed before the market open, leaving the stock set for suspension on Dec. 31. Merus last traded around $90 late Monday, about 7% below its prior close, according to market data. NASDAQ Trader

30 December 2025

NASDAQ:GMAB·NASDAQ:MRUS·Stock Market

AbbVie stock price: ABBV heads into Tuesday with epcoritamab trial in the crosshairs

AbbVie stock slides after Epkinly trial misses survival goal — what ABBV investors watch next

AbbVie stock heads into long weekend lower after mixed Epkinly trial readout; earnings next

Genmab stock slides today as GMAB shelves acasunlimab; Merus takeout steps in focus

GMAB stock slides as Genmab scraps late-stage acasunlimab cancer therapy

Merus stock halted today as Genmab buyout closes: what happens to MRUS shares and the $97 cash payout

TechStock² Updates

Marvell Shares Drop 10.3%, Wiping Out $22 Billion Amid Google Revenue Delay to 2029

Ambev Shares Slide 0.7%, 30 Million Shares Test 31.6% Margin Rebound

Coeur Mining Stock Falls 4.9%, Erasing $1.1 Billion as Metals Slide

B2Gold Reports Masbate Fatality After Stock Falls 2.9%; Production Continues

IREN Shares Drop 12.5% With $4 Billion AI Expansion Pushing Up Against $6.4 Billion Financing Hurdle

NVIDIA Sheds 4.6% and Loses $252 Billion in Value as Margin Concerns Emerge Over Memory Prices

SpaceX Shares Edge Up 0.5% with $1.86 Trillion Value as Quarterly Capex Hits $18.4 Billion

Intel Shares Drop 2.9%, Remain 5.8% Under $95 Offering as Company Delivers 25% Revenue Gain

PG&E Shares Drop 7.5%, Wiping Out $3 Billion After Delay to California Wildfire Shield

DraftKings Faces $67.6 Million Loss on $13.1 Billion U.S. Open Betting Volume

Investment Disclaimer